These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21375570)

  • 1. Rilonacept and canakinumab.
    Dubois EA; Rissmann R; Cohen AF
    Br J Clin Pharmacol; 2011 May; 71(5):639-41. PubMed ID: 21375570
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
    Savic S; McDermott MF
    Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
    [No Abstract]   [Full Text] [Related]  

  • 4. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
    Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
    Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Future of IL-1 Targeting in Kidney Disease.
    Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
    Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab in pediatric rheumatic diseases.
    Wulffraat NM; Woo P
    Expert Opin Biol Ther; 2013 Apr; 13(4):615-22. PubMed ID: 23451862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab.
    Dhimolea E
    MAbs; 2010; 2(1):3-13. PubMed ID: 20065636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome.
    Egawa M; Imai K; Mori M; Miyasaka N; Kubota T
    J Clin Immunol; 2017 May; 37(4):339-341. PubMed ID: 28386702
    [No Abstract]   [Full Text] [Related]  

  • 18. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
    Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab.
    Mueller SM; Itin P; Haeusermann P
    Skinmed; 2013; 11(2):80-3. PubMed ID: 23745225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.